Introduction: Apalutamide is an androgen receptor (AR) inhibitor developed by the University of California, USA. The drug was licensed to Aragon Pharmaceuticals in 2009. In February 2018, apalutamide was approved by the US FDA for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC).
Structural formula:
Properties
Summary
ARN-509 is a selective, competitive androgen receptor inhibitor with IC50 of 16 nM, effective in the treatment of prostate cancer.
CRO
